Steven Cohen Aptinyx Inc. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $0.69 $49,249 - $283,187	-410,416 Closed	0 $0
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $267,741 - $1.82 Million	-704,584 Reduced 63.19%	410,416 $229,000
Q1 2022 May 16, 2022	BUY	$2.27 - $3.62 $2.15 Million - $3.43 Million	947,396 Added 565.26%	1,115,000 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$2.11 - $3.0 $353,644 - $502,812	167,604 New	167,604 $448,000
Q1 2019 May 15, 2019	SELL	$3.99 - $19.33 $1.77 Million - $8.57 Million	-443,595 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$16.15 - $28.93 $7.16 Million - $12.8 Million	443,595 New	443,595 $7.34 Million
Q3 2018 Nov 14, 2018	SELL	$20.21 - $31.85 $606,300 - $955,500	-30,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$19.83 - $24.17 $594,900 - $725,100	30,000 New	30,000 $725,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.